120 related articles for article (PubMed ID: 8474285)
21. Endotoxin antibody for sepsis in infants.
Nadel S; Klein N; Heyderman R; Levin M
Lancet; 1992 Mar; 339(8794):678. PubMed ID: 1347362
[No Abstract] [Full Text] [Related]
22. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia.
Opal SM; Palardy JE; Parejo N; Jasman RL
Crit Care Med; 2003 Mar; 31(3):929-32. PubMed ID: 12627007
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of endotoxin and antiendotoxin antibodies in patients with multiple injuries: a prospective clinical study.
Buttenschoen K; Berger D; Hiki N; Strecker W; Seidelmann M; Beger HG
Eur J Surg; 1996 Nov; 162(11):853-60. PubMed ID: 8956953
[TBL] [Abstract][Full Text] [Related]
24. Case 1: Chronic meningococcemia.
Sayre JW
Pediatr Rev; 1992 Jul; 13(7):269-70. PubMed ID: 1620670
[No Abstract] [Full Text] [Related]
25. Life-threatening eruptions due to infectious agents.
Ramos-e-Silva M; Pereira AL
Clin Dermatol; 2005; 23(2):148-56. PubMed ID: 15802208
[TBL] [Abstract][Full Text] [Related]
26. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
Tebas P
Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
[No Abstract] [Full Text] [Related]
27. Cardiac tamponade as a delayed presentation of Neisseria meningitidis infection in a 5-month-old infant.
Gupta S; Rudolph G
Pediatr Emerg Care; 2007 Mar; 23(3):163-5. PubMed ID: 17413432
[TBL] [Abstract][Full Text] [Related]
28. Antiendotoxin monoclonal antibodies. What future now?
Susla GM; Dew RB
Drug Saf; 1994 Oct; 11(4):215-22. PubMed ID: 7848542
[No Abstract] [Full Text] [Related]
29. Centoxin: the full story of its withdrawal.
Andrews PA
Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490693
[No Abstract] [Full Text] [Related]
30. Centoxin: the full story of its withdrawal.
Choyce MQ
Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490694
[No Abstract] [Full Text] [Related]
31. Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.
Hurley JC
Drugs; 1994 Jun; 47(6):855-61. PubMed ID: 7521827
[No Abstract] [Full Text] [Related]
32. Could natural inhibitors of tumor necrosis factor-alpha modify the clinical course of fulminant meningococcemia?
Villard J; Roux-Lombard P; Hugli A; Dayer JM
Crit Care Med; 1993 Sep; 21(9):1396-400. PubMed ID: 8396525
[No Abstract] [Full Text] [Related]
33. Parents' and GPs' key role in diagnosis of meningococcal septicaemia.
van Deuren M; Brandtzaeg P
Lancet; 2000 Sep; 356(9234):954-5. PubMed ID: 11041389
[No Abstract] [Full Text] [Related]
34. Fulminant meningococcal septicemia: dissociation between plasma thrombopoietin levels and platelet counts.
Bjerre A; Ovstebø R; Kierulf P; Halvorsen S; Brandtzaeg P
Clin Infect Dis; 2000 Apr; 30(4):643-7. PubMed ID: 10770723
[TBL] [Abstract][Full Text] [Related]
35. Meningococcal disease as a model to evaluate novel anti-sepsis strategies.
Cohen J
Crit Care Med; 2000 Sep; 28(9 Suppl):S64-7. PubMed ID: 11007201
[TBL] [Abstract][Full Text] [Related]
36. Systemic meningococcal infection and complement deficiency.
Leggiadro RJ
Pediatr Infect Dis J; 2003 Aug; 22(8):760-1. PubMed ID: 12913784
[No Abstract] [Full Text] [Related]
37. Anti-endotoxin monoclonal antibodies.
Wheeler AP; Bernard GR
N Engl J Med; 1992 Sep; 327(12):889-90. PubMed ID: 1508255
[No Abstract] [Full Text] [Related]
38. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
Quintiliani R; Cooper B; Maderazo E; Nightingale C
Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
[TBL] [Abstract][Full Text] [Related]
39. Anti-endotoxin monoclonal antibodies.
Jackson JE
N Engl J Med; 1992 Sep; 327(12):889; author reply 890-1. PubMed ID: 1508253
[No Abstract] [Full Text] [Related]
40. Anti-endotoxin monoclonal antibodies.
Stone DJ
N Engl J Med; 1992 Sep; 327(12):889; author reply 890-1. PubMed ID: 1342784
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
